Richard Fisher,

President & CEO

Dr. Richard Fisher is an inventor, entrepreneur, and scientist with a focus on gene therapy and non-viral drug delivery systems. With over a decade of experience in preclinical and clinical trial development of non-viral delivery systems, Dr. Fisher is poised to lead Orion Therapeutics into the future with goal of developing the most potent delivery technologies that will unleash a multitude of gene therapy solutions for previously undruggable diseases.


Michael McCaman, PhD

Vice President & Chief Strategy Officer

Dr. Michael McCaman is an author and experienced business leader in the field of biotechnology with 35 years experience in pharmaceutical development of biological therapeutics including proteins, antibodies, cell therapies, and viral/non-viral delivery systems. Dr. McCaman’s specialties range from formulation and process development to CMC and commercialization of drug products. He is widely published with more than 25 peer-reviewed journal articles and several book chapters and reviews in pharmaceutical drug development.


Deidra Mountain, PhD

Director of Vascular Therapeutics Pipeline

Dr. Deidra Mountain is an inventor, entrepreneur, and professor with a focus on novel therapeutic modalities to treat vascular disease and vascular injury. Dr. Mountain's preclinical research has led to the discovery of several gene therapy targets with the potential to revolutionize treatments for vascular disease patients and is co-inventor of LNP technology used herein to deliver RNA therapeutics to the human vasculature.


Jennifer Zachry, PhD

Director of Business Development

Jennifer Zachry is a PhD candidate in the Vanderbilt Department of Pharmacology. She recently competed in the Scipreneur Challenge, an entrepreneurship-based competition in which she lead a team to create a business plan around Orion Therapeutics (Finalist). She has consulted for entities at Vanderbilt and served in a business development role at Nashville Biosciences. She is seeking to apply her interdisciplinary knowledge in the sciences and experience with project management and business development to commercialize Orion Therapeutics Inc.



Chad Seaver, PhD

CEO & Board Director Chief Executive Officer Arkis BioSciences

Responsible for business organization and development, capital fundraising, finance, product development leadership, and commercialization at Arkis BioSciences. Over twenty years experience, including more than ten years in senior management, leading the development and commercialization of new medical devices with private-to-public ventures and global conglomerates.


Michael Freeman, MD

Professor of Surgery, Chief, Division of Vascular and Endovascular Surgery, Department of Surgery Chair, University of Tennessee Graduate School of Medicine

 Dr. Freeman attended the Medical College of Georgia where he graduated with Alpha Omega Alpha honors and completed general surgery residency and a vascular surgery fellowship at Barnes Hospital/Washington University School of Medicine in St. Louis.

Dr. Freeman has been Program Director for the Vascular Surgery Fellowship Program and Chief of the Division of Vascular Surgery. He is a highly respected clinician across multiple national and regional professional societies, holding positions on the Executive Board of The Society for Vascular Surgery and the Executive Council of the Southern Association for Vascular Surgery.


Joshua Bradley, JD, MBA

Attorney at Farris Bobango Branan PLC

  Attorney practicing in the areas of general civil and commercial litigation, business development and strategy. Received J.D. and M.B.A. from the University of Memphis School of Law and Fogelman College of Business in May 2015

Contact Us for Your Delivery Solution Needs

Are you seeking innovative delivery solutions for your RNA therapeutics? At Orion Therapeutics, we specialize in providing a versatile LNP platform that can deliver various types of RNA payloads across a wide range of disease indications. We would love to collaborate with you to address your specific delivery challenges and help advance your research or clinical projects.